Glucagon-like peptide-1 receptor (GLP-1R)

Overview

The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), encoded by GLP1R (Wikidata: Q14909910), is a class B G protein-coupled receptor expressed in pancreatic β-cells, the gastrointestinal tract, heart, kidney and select regions of the central nervous system. Its endogenous ligand, glucagon-like peptide-1 (GLP-1), is released by intestinal L-cells after a meal and degraded within minutes by Dipeptidyl peptidase 4 (DPP-4) — a half-life so short that every therapeutic agonist is built to evade that enzyme. Binding engages the two-domain mechanism typical of class B receptors, the peptide's C-terminus docking to the large extracellular domain while its N-terminus inserts into the transmembrane core, and couples through Gs to raise cyclic AMP. The downstream effectors, protein kinase A and the guanine nucleotide exchange factor Epac2, act on the β-cell's exocytotic machinery in a way that amplifies insulin release only when glucose is already elevated — the reason receptor agonists lower glucose without causing hypoglycemia on their own.

Through this pathway the receptor stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying and reduces food intake. Those effects have made it one of the most important drug targets of the past two decades: liraglutide, semaglutide and the dual GIP/GLP-1 co-agonist tirzepatide are in wide use for type 2 diabetes and obesity, and the same agents reduce cardiovascular events and slow kidney disease progression. Which signals a given agonist favors, and how quickly the receptor internalizes after binding, differ between drugs and are now explicit design variables rather than incidental properties.

Outside the pancreas the receptor mediates gut-brain signaling, linking intestinal and hormonal cues to appetite, reward and mood circuitry, which underlies interest in addiction and neuropsychiatric indications. GLP-1R-targeted imaging is being investigated as a way to assess functional β-cell mass non-invasively, an approach that remains investigational rather than validated. Its roles in heart failure risk reduction, anticancer signaling and multi-target drug design continue to broaden the receptor's reach across disease areas.

Recent Publications Summary

Recent publications on GLP-1R centered on expanding the therapeutic and pharmacologic scope of receptor targeting, particularly in obesity, diabetes, and metabolic disease. Several studies evaluated multi-agonist or dual-target approaches that retained GLP-1R activity, including a liver-targeted GLP-1 receptor and glucagon dual agonist for metabolic dysfunction–associated steatotic liver disease and MASH 42480572Jul, a dual GLP-1/APJ receptor agonist designed to improve cardiovascular-kidney-metabolic syndrome in type 2 diabetes 42401045Jul, a trispecific GLP-1/GIPR/FGF21 peptibody with favorable metabolic effects in diet-induced obesity 42372355Jun, and a glucagon/GLP-1 receptor dual agonist, mazdutide, tested in a phase 3 obesity trial 42251595Jun. Across these studies, GLP-1R engagement was associated with improved metabolic endpoints, including body weight reduction, glycemic control, and organ-protective effects, while some investigations also explored GLP-1R in combination strategies aimed at broader metabolic remodeling.

A second cluster of publications focused on improving GLP-1R-directed drug design and durability. semaglutide-derived lactam-stapled peptide scaffolds were designed to preserve GLP-1R engagement while enhancing serum and proteolytic stability, with several candidates showing favorable stability profiles and receptor-compatible modeling predictions 42578506Aug. In parallel, an IgG Fc-binding motif-conjugated exendin-4 analogue was developed to extend plasma half-life while retaining robust GLP-1R activation and glucose-lowering activity, with chronic dosing in db/db mice rivaling semaglutide for HbA1c reduction and pancreatic islet protection 42216891May. Another study described a subcutaneous nanoparticle platform using exenatide to leverage GLP-1R affinity for pancreatic targeting, with the formulation designed to support beta-cell preservation 42393437Jul. In addition, in silico discovery efforts identified candidate oral GLP-1R agonists or multipotent molecules, including Fmol021, which showed predicted stability within the GLP-1R orthosteric pocket 42162325May, and fragment-guided approaches also highlighted GLP-1R as a tractable target for lead discovery 41601187Jan.

Several publications examined GLP-1R biology in nontraditional disease contexts and tissues. In rodent models, systemic liraglutide acting through GLP-1R-expressing neurons in the lateral septum was linked to reduced alcohol intake and seeking 42385677Jul. In the brain, an oral, blood-brain barrier-penetrant GLP-1R agonist, OHP2, was reported to act primarily on astrocytes and to promote astrocyte-neuron lactate and lipid transfer with neuroprotective effects in an Alzheimer’s disease-related metabolic model 42330959Jun, whereas preventive semaglutide or tirzepatide treatment did not alter neuropathological progression in 5xFAD mice despite effects on body weight and glucose tolerance 42413499Jul. liraglutide was also reported to improve postoperative cognitive impairment in aged mice through GLP-1R/NRF2 pathway activation and suppression of NLRP3 inflammasome signaling 42102962May, and another study described rapid antidepressant-like effects of a Chinese medicine formula via sequential activation of hippocampal GLP-1 receptor and PACAP signaling 42034172Apr. Outside neurology, GLP-1R was implicated in inflammatory and oncologic models, including Dendrobium huoshanense polysaccharides acting through the GLP-1/GLP-1R axis in ulcerative colitis 41962608Apr and combined GLP-1R and IL-17A targeting suppressing obesity-induced leukemia in a PTPN11 mutation-driven model 42334870Jun.

GLP-1R was also investigated as a biomarker and as a functional receptor in human disease studies. A GLP-1R-targeted PET tracer, [18F]FB(ePEG12)12-exendin-4, enabled quantitative imaging of pancreatic beta-cell mass in type 1 diabetes, with lower pancreatic uptake in affected individuals and correlations with fasting C-peptide index, HbA1c, and insulin dose 41814494Mar. Mendelian randomization analysis suggested novel beneficial effects of GLP-1R agonists in heart failure 41609518Jan, while a selective GLP-1R antagonist, imapextide, was evaluated in healthy volunteers as a sustained-action candidate for postbariatric hypoglycemia 41437319Dec. Together, these recent publications depict GLP-1R as a versatile target spanning peptide engineering, metabolic therapy, neurobiology, inflammatory disease, imaging, and antagonist development 42578506Aug42401045Jul42330959Jun41814494Mar41437319Dec.

What Changes, What Holds

1. GLP-1R now looks like a modular platform for broader metabolic co-targeting
REINFORCES Multi-agonist and dual-target constructs that keep GLP-1R activity mainly extend the receptor’s established metabolic role rather than revising it. The important change is strategic: GLP-1R is increasingly being used as a backbone for liver, cardiovascular-kidney-metabolic, and obesity programs, with improved weight and glycemic outcomes still fitting the baseline expectation that receptor engagement drives metabolic benefit. The open question is not whether GLP-1R works, but how far combination design can broaden organ protection without sacrificing specificity 42480572Jul42401045Jul.

2. Drug design is moving toward longer-acting, more stable GLP-1R agonists
METHOD Stapled scaffolds, Fc-assisted half-life extension, nanoparticle targeting, and in silico lead finding do not change what GLP-1R does; they change how it is engineered and delivered. The baseline already noted that agonist behavior and receptor internalization are design variables, and this work sharpens that point by showing multiple ways to preserve GLP-1R engagement while improving durability, stability, or tissue targeting. The consequence is a stronger medicinal-chemistry toolkit, not a new biological role 42578506Aug42216891May.

3. GLP-1R has credible roles in brain and inflammatory disease beyond glucose control
NEW DIRECTION liraglutide’s action through GLP-1R-expressing lateral septal neurons links the receptor to alcohol-seeking behavior, and the astrocyte-focused Alzheimer’s model plus postoperative cognitive and inflammatory findings place GLP-1R in neuroprotection and immune modulation. The Overview already mentions appetite, reward and mood circuitry, so the alcohol result extends that axis rather than contradicting it; the disease-model papers, however, broaden GLP-1R into contexts not previously established there. Mixed results in 5xFAD mice caution that these CNS benefits remain model-dependent 42385677Jul42330959Jun.

4. GLP-1R is becoming both a biomarker and a druggable antagonist target
NEW DIRECTION PET imaging of pancreatic beta-cell mass strengthens the already investigational imaging role and makes the receptor more usable as a disease-readout in type 1 diabetes, while the healthy-volunteer antagonist study shows GLP-1R can be deliberately blocked for postbariatric hypoglycemia. The Mendelian-randomization signal for heart failure supports the baseline’s cardiovascular interest, but the antagonist work is the main addition because it introduces a clinically relevant use in the opposite direction to agonism. Together they widen GLP-1R from a therapy target to a measurable and, in some settings, suppressible system 41814494Mar41437319Dec.

Overview update candidates: GLP-1R as a broader neurobehavioral and inflammatory target; GLP-1R antagonism for postbariatric hypoglycemia; quantitative GLP-1R PET for beta-cell mass in type 1 diabetes.